Hey Ezzra - Agree the call was promising. They continue to execute on their clear strategy to grow the business.
What I see right now is a lot of blocking and tackling. Doesn't necessary look fantastic on a financial statement, but solid fundamentals of growing the business, laying the groundwork, and sticking to their plan will lead to a lot of points at the end of the game.
Since the begining of the year they have:
1. Released TACT study showing great clinical data.
2. Received FDA clearance for domestic sales of Tulsa PRO.
3. Completed an uplisting to NASDAQ,
4. Continued to grow internationally.
5. Sold first TULSA in Japan with first treatments starting in October.
6. Sold first TULSA unit in US
7. Continued to grow Sonalleve with 2 new purchase orders in hand with Q4 install dates. Revenue not yet recognized!
8. Continued to grow their US sales and installation team.
9. Continuing to progress through clinical trials for added data and added uses.
10. Strengthened their balance sheet with added funding. Yes, offerings suck, but they are a necessary evil and I believe they did it right.
11. Picked up additional analyst coverage led by Raymond James who all place buy rating with huge growth projections.
I see a bright future ahead. Bumps in the road - yeah probably, but I am still bullish on these guys and their proven management team. Full transparency: I am long, but that doesn't make me right! Do your own DD! Good luck everyone!
